UK markets closed
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • FTSE 250

    19,123.71
    +430.73 (+2.30%)
     
  • AIM

    896.27
    +10.41 (+1.18%)
     
  • GBP/EUR

    1.1618
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • BTC-GBP

    17,547.31
    +405.16 (+2.36%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.32 (+2.68%)
     
  • CRUDE OIL

    107.06
    +2.79 (+2.68%)
     
  • GOLD FUTURES

    1,828.10
    -1.70 (-0.09%)
     
  • NIKKEI 225

    26,491.97
    +320.72 (+1.23%)
     
  • HANG SENG

    21,719.06
    +445.19 (+2.09%)
     
  • DAX

    13,118.13
    +205.54 (+1.59%)
     
  • CAC 40

    6,073.35
    +190.02 (+3.23%)
     

Global Cancer Therapies Market to Reach $204.2 Billion by 2024

·26-min read
ReportLinker
ReportLinker

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Cancer Therapies Market to Reach $204.2 Billion by 2024

Cancer is ranked among the leading diseases resulting in mobility and mortality. Cancer treatments or therapies are aimed at eliminating or slowing down growth of cancerous abnormal cells by interfering with specific molecules like DNA or proteins that contribute to growth of cancerous cells. Global market for cancer therapies continues to witness robust growth driven by the increasing prevalence of various types of cancers across the world. Amid the COVID-19 crisis, the global market for Cancer Therapies is projected to reach US$204.2 Billion by 2024, registering a compounded annual growth rate (CAGR) of 9.7% over the analysis period. United States represents the largest regional market for Cancer Therapies, accounting for an estimated 38.3% share of the global total. The market is projected to reach US$86.7 Billion by the close of the analysis period. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 11.2% over the analysis period.

The development and increased availability of accurate and highly effective treatment options, led by technology advancements and increase investments into R&D indicatives, is expected to fuel growth. The rapid aging population at a higher risk of developing cancer also presents growth opportunities for the market. Standard cancer treatments such as chemotherapy, radiation therapy, surgery, given their relatively higher side effects and disadvantages, are forecast to be elbowed aside by new biotherapy and immunological treatments, which are expected to spruce up growth. However, the significantly higher cost of developing cancer drugs and potential for side effects with various cancer therapies are limiting market growth. The growing population of cancer patients in the US represents a major growth driving factor. The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major player in the cancer therapies market. Asia-Pacific is poised to grow at a high rate due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region.

The market for Biotherapies is forecast to emerge as the dominant segment over the analysis period. The segment features several drugs that have attained blockbuster status and sales of these drugs continue to rise with each passing year. Factors such as increasing number of new and overall cancer patients worldwide, as well as the relative higher efficacy and safety profiles of biotherapies are further expected to fuel sales in this segment.
Select Competitors (Total 80 Featured) -

  • AbbVie, Inc.

  • Amgen, Inc.

  • Astellas Pharma, Inc.

  • AstraZeneca Plc.

  • Bayer AG

  • Bristol-Myers Squibb Company

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd.

  • Glaxosmithkline Plc

  • Johnson & Johnson Services, Inc.

  • Merck KGaA

  • Novartis AG

  • Pfizer, Inc.

  • Takeda Pharmaceutical Company Limited.




Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Cancer Therapies: An Outlook
Chemotherapy & Targeted Therapy Lead the Global Cancer
Therapies Market
By Cancer Type
USA Leads the Cancer Therapies Market
Biotherapies to Drive Growth
Rise in Cancer Incidence & Access to Modern Therapeutics Foster
Growth
Total Number of New Cancer Cases by Type: 2018
Total Number of Cancer Deaths by Type: 2018
Cancer Incidence by Region: 2018
Cancer Mortality by Region: 2018
Age-Standardized Incidence and Mortality Rates of All Cancers
(per 100000 Population) by Region: 2018
Cancer Research Spending Continues to Witness Growth
Number of FDA-Approved Cancer Drugs: 2010-2018
Select Cancer Drug Approvals in 2019
Select Cancer Drug Approvals in 2018
Cancer Drug Pipeline to Change the Pharma Landscape
Increasing Share of Cancer Drugs as % Of Total Pharma Drug
Pipeline: 2010-2019
Cancer Therapies - Global Key Competitors Percentage Market
Share in 2022 (E)
Select Leading Cancer Drugs Worldwide by Sales: 2018
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS
AbbVie, Inc. (USA)
Amgen, Inc. (USA)
Astellas Pharma, Inc. (Japan)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Select Late Stage Compounds in Bristol-Myers Squibb Company?s
Oncology Pipeline (As of 2019)
Celgene Corporation (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Glaxosmithkline Plc (UK)
Johnson & Johnson Services, Inc. (USA)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS
Industry Focuses on New Approaches to Treat Cancer
Recent Advancements in Cancer Drug Discovery
A New Immunotherapy Technique that Improves Efficacy and Safety
of Cancer Treatment Developed by an Institute for Molecular
Engineering Research Team
Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
New Linker Technology for Enhancing Stability of ADCs
Personalized Medicine Gains Importance
Companion Diagnostics Accelerate Role of Personalized Medicine
in Cancer Care
North American Companion Diagnostics Market (2019)
European Companion Diagnostics Market by Disease Area (2019)
Innovations in Cancer Drug Delivery: Key Factor in Product
Differentiation
Peptoid-based Nanotubes Allow Precise, Targeted Delivery of
Cancer Drugs
Combination Therapy: A Double Whammy Success
Patent Expiries of Branded Drugs to Trigger Generic Competition
Patent Expiries of Major Biopharmaceutical Drugs in the US and
Europe
Gene Therapy based Approaches Present Potential Weapon for
Battle against Cancer
Development of Novel Drug Candidates and Potential Therapies
Non-Viral Gene Therapy to Expedite Cancer Research and
Introduction of New Therapies
Rise in Patient Assistance Programs (PAPs)
Top Financial Concerns for Cancer Patients: Ranked In Order of
Influence
Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket
Expenses
Growth Drivers and Restraints
Demographics & Lifestyles Raise the Risk of Cancer
Percentage Breakdown of New Cases for All Cancers by Gender (2019)
Percentage Breakdown of New Cases for Colon and Rectum Cancers
by Gender (2019)
Percentage Breakdown of New Cases for Lung & Bronchus Cancers
by Gender (2019)
Unmet Needs Leave Scope for Further Research and Development
Low Entry Barriers in Cancer Research Encourages Breakthrough
Developments
Increasing Investments by National Health Authorities
NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
Improved Screening, Diagnosis & Patient Survival Rates Trigger
Growth
Molecular Imaging of Cancer: Critical in Improving Patient
Outcomes
Innovations, Improvements, and Approvals Propel Growth
Select Cancer Drug Approvals (2018 & 2019)
Emerging Challenges in Cancer Drug Development
Drug Failures Deter Prospects of New Therapies
High Prices of Targeted Therapies Act as a Speed Breaker
Estimated Average Monthly Cost of Select Leading Cancer Drugs
in the US as of 2016
Cancer Drug Approval Processes Need to Become More Flexible for
Encouraging Innovation
Limited Tumor Specificity and Toxicity
Complicated Treatment Protocols: A Major Stumbling Block in
Patient Compliance
Reduced Smoking
Global Cigarette Consumption Per Capita by Select Countries for
1970 and 2018
Reimbursement Coverage Remains a Major Challenge
Increase in Multidrug Resistance
Stringent Regulations Delay Market Approval
Challenges Encountered in Clinical Trials
Overview of Cancer Therapy Segments
Immunotherapy: A Promising Segment
Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
Monoclonal Antibodies for Cancer Treatment
Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer
Treatment
Vaccines: A Promising Future Area of Cancer Therapeutics
Approved Therapeutic Cancer Vaccines Worldwide
CAR-T Therapy: An Innovative Therapy Focused on Engineering of
Patients? Immune Cells for Cancer Treatment
UK Researchers New Approach Holds Potential to Boost
Immunotherapies
Targeted Therapy: An Overview
Types of Targeted Therapy
Chemotherapy: An Overview
Types of Chemotherapy
Risks Associated with Chemotherapy
Hormone Therapy
Drug Classes in Hormone Therapy
CANCER TYPES, APPROVED AND PIPELINE DRUGS
Prostate Cancer
Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
Select General Risk Factors and their Relative Risk Rate in
Prostate Cancer
Select FDA Approved Drugs for Palliative Treatment of Advanced
Prostate Cancer
Select Drugs that Received Approval for Castration-Resistant
Prostate Cancer (CRPC)
Prostate Cancer Phase IV Completed Clinical Trials with Results
Lung Cancer
Age-Standardized Lung Cancer Rates for Select Countries
Age-Standardized Lung Cancer Rates in Men for Select Countries
Age-Standardized Lung Cancer Rates in Women for Select Countries
Select FDA-Approved Non-Small Cell Lung Cancer Drugs
Select Phase IV Completed Clinical Trials with Results: As of
Dec, 2019
Select Phase III Completed Clinical Trials with Results: As of
December 30, 2019
Breast Cancer
Select FDA Approved Breast Cancer Drugs
Breast Cancer Phase IV Completed Clinical Trials with Results:
As of Dec 30, 2019
Breast Cancer Select Phase III Completed Clinical Trials with
Results: As of Dec 30, 2019
Renal Cancer
Select FDA-Approved Renal Cell Carcinoma Drugs
Cervical Cancer
Colorectal Cancer
Select FDA-Approved Colorectal Cancer Drugs
Skin Cancer
Pancreatic Cancer
Non-Hodgkin?s Lymphoma
Leukemia
Standard Approved Mode of Therapy for AML by Age Group
Blood Cancer Phase IV Completed Clinical Trials with Results:
As of Dec 30, 2019
Blood Cancer Phase III Completed Clinical Trials with Results:
As of Dec 30, 2019
Bladder Cancer
Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Cancer Therapies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Cancer Therapies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Cancer Therapies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Hormonal Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Hormonal Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Hormonal Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Other Treatment Types by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Treatment Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Treatment Types
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Blood Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Blood Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Blood Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Breast Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Breast Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Breast Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Prostate Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Prostate Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Prostate Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Gastrointestinal Cancer by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Gastrointestinal Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Gastrointestinal Cancer
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Gynecologic Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Gynecologic Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Gynecologic Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 34: World Recent Past, Current & Future Analysis for
Other Cancer Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cancer Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cancer Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 37: World Recent Past, Current & Future Analysis for Lung
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Lung Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Lung Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2022 (E)
Market Overview
Rising Cancer Cases Spur Growth in Cancer Therapies Market
Estimated Number of New Cancer Cases and Deaths in the US (2019)
Number of Cancer Drugs in Development for the Years 2006, 2009,
2012, 2015 and 2018
Number of FDA-Approved Oncology Drugs in the US (2010-2018)
Cancer Drugs as % of Drug Pipeline in the US for the Period
2010-2019
Patient Assistance Programs Alleviate Cost Burden of Patients
to Some Extent
Personalized Medicine Gathers Momentum for Cancer Treatment in
the US
A Surging US Prostate Cancer Therapeutics Market
Medicaid Reimbursement Rates for Cancer Treatment with
Radiation Indicate Notable Disparity among States
Oncology Care Model to Improve Quality and Reduce Financial
Toxicity of Cancer Care
CMS Hikes Reimbursement Rate for CAR-T Therapy
Market Analytics
Table 40: USA Recent Past, Current & Future Analysis for Cancer
Therapies by Treatment Type - Chemotherapy, Targeted Therapy,
Immunotherapy, Hormonal Therapy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Cancer Therapies by Treatment
Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal
Therapy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 42: USA 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 43: USA Recent Past, Current & Future Analysis for Cancer
Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 44: USA Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

CANADA
Number of New Cancer Cases in Canada: 2019
Table 46: Canada Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 50: Canada Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

JAPAN
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2022 (E)
Table 52: Japan Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 55: Japan Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 56: Japan Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

CHINA
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2022 (E)
Cancer Therapies Market: Overview
Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
Chinese Drug Makers Look to Strengthen Domestic Presence with
Low-cost Products
Table 58: China Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 62: China Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

EUROPE
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2022 (E)
Rising Cancer Incidence and New Drug Development Augur Well for
European Cancer Therapies Market
Cancer Incidence in Europe: Number of New Cancer Cases
(in Thousands) by Site for 2018
Number of New Cancer Cases Diagnosed (in Thousands) in the UK:
2018
Table 64: Europe Recent Past, Current & Future Analysis for
Cancer Therapies by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 65: Europe Historic Review for Cancer Therapies by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Cancer Therapies by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 67: Europe Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 71: Europe Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

FRANCE
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2022 (E)
Table 73: France Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 74: France Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: France 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 76: France Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 77: France Historic Review for Cancer Therapies by Cancer
Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

GERMANY
Cancer Therapies Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2022 (E)
Table 79: Germany Recent Past, Current & Future Analysis for
Cancer Therapies by Treatment Type - Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR

Table 80: Germany Historic Review for Cancer Therapies by
Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy,
Hormonal Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 81: Germany 15-Year Perspective for Cancer Therapies by
Treatment Type - Percentage Breakdown of Value Sales for
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
and Other Treatment Types for the Years 2012, 2021 & 2027

Table 82: Germany Recent Past, Current & Future Analysis for
Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer,
Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer,
Lung Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 83: Germany Historic Review for Cancer Therapies by
Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer,
Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and
Other Cancer Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Germany 15-Year Perspective for Cancer Therapies by
Cancer Type - Percentage Breakdown of Value Sales for Blood
Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal
Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types
for the Years 2012, 2021 & 2027

ITALY
Table 85: Italy Recent Past, Current & Future Analysis for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting